The incidence of disseminated candidiasis has increased dramatically over the past several decades. Fortunately, in recent years, a variety of new antifungal agents have become available to treat these infections. On the basis of efficacy, safety, and cost considerations, fluconazole is the agent of choice for the empirical treatment of disseminated candidiasis in nonneutropenic, hemodynamically stable patients, unless a patient is suspected to be infected with an azole-resistant species (i.e., Candida glabrata or Candida krusei). For hemodynamically unstable or neutropenic patients, agents with broader species coverage, such as polyenes, echinocandins, or, possibly, voriconazole, are preferred for empirical treatment of candidemia. Modification of the initial, empirical regimen depends on the response to therapy and the subsequent identification of the species of the offending pathogen. Echinocandins or high-dose polyenes are preferred for the treatment of infections with C. glabrata or C. krusei. Central venous catheters should be removed from all patients who have disseminated candidiasis, if feasible, and antifungal therapy should be administered to all patients who have candidemia or proven candidiasis.
increasing incidence of these risk factors in the aging population, as well as the increasingly intensive care administered to critically ill, hospitalized patients, disseminated candidiasis will likely continue to be a major cause of nosocomial infections in the coming years.
For decades, only one class of antifungal agents, the polyenes, was available for the treatment of disseminated candidiasis. However, with the advent of reliably active azoles, safer lipid formulations of amphotericin, and the novel echinocandin class of antifungals, clinicians are now in the enviable position of being able to choose from among multiple antifungal agents for the treatment of disseminated candidiasis. The purpose of the present review is to rationally compare the antifungal agents currently available for the treatment of these infections.
ANTIFUNGAL OPTIONS FOR THE TREATMENT OF DISSEMINATED CANDIDIASIS
Antifungal options available for the treatment of disseminated candidiasis are summarized in table 2.
Polyenes. Amphotericin B deoxycholate, which has been the reference standard for the treatment of disseminated candidiasis for 50 years [12] , demonstrates rapidly cidal in vitro activity against virtually all strains of Candida albicans. However, there are increasing concerns about the activity of amphotericin B deoxycholate against other Candida species (see below). Furthermore, toxicities are frequently associated with amphotericin and may be severe. In an effort to reduce the b Mean time to onset of infection in a recent, large, prospective study was day 22 of hospitalization [1] . c HIV infection and diabetes mellitus predominantly predispose to mucocutaneous candidal infections, and diabetes is also a risk factor for disseminated disease; HIV infection is a cofactor for, but not an independent risk factor for, disseminated disease.
nephrotoxicity associated with amphotericin, the agent has been reformulated into various lipid-based derivatives, including liposomal amphotericin B and amphotericin B lipid complex. Unfortunately, the lipid formulations are considerably more expensive than amphotericin [13] . The effect of this increase in cost is significant, especially at hospitals with limited financial resources. Nonrandomized trials have demonstrated that both liposomal amphotericin B and amphotericin B lipid complex are effective treatments for patients with disseminated candidiasis [14] [15] [16] , and these drugs have been approved by the US Food and Drug Administration for use in patients with proven invasive candidiasis who are refractory to or intolerant of amphotericin B deoxycholate. Because the lipid-based formulations have superior side-effect profiles, their doses can be substantially increased. For example, published nonrandomized studies used lipid-based amphotericin at 3-7 mg/kg/day, which is up to 10-fold greater than standard doses of amphotericin B deoxycholate. Furthermore, it is now clear that liposomal amphotericin B doses up to, and possibly exceeding, 15 mg/ kg/day are well tolerated [17] . This finding indicates that clinical trials may have underestimated the maximum efficacy of liposomal amphotericin B by testing lower doses of the drug.
Once the decision to use a lipid-based formulation of amphotericin has been made, there is little to guide the choice between liposomal amphotericin B and amphotericin B lipid complex. These agents have been compared in 2 head-to-head clinical trials, 1 involving patients receiving empirical treatment for neutropenic fever [6] and 1 involving patients with suspected or proven fungal infections [18] . Both studies found that the 2 agents had equivalent efficacies. One of the 2 studies found liposomal amphotericin B to be less nephrotoxic than amphotericin B lipid complex [6] , whereas the second study found that these agents produced a similar nephrotoxicity [18] . Because very few patients with known candidemia were enrolled in these trials, recommendations regarding which agent is preferred for the treatment of disseminated candidiasis cannot be made on the basis of the available data.
Azoles. Although polyenes clearly have superior in vitro activity against Candida species compared with fluconazole, 2 large, multicenter, randomized studies have demonstrated unequivocally that fluconazole and amphotericin B deoxycholate have equivalent efficacies in nonneutropenic patients with candidemia [7, 8] . Fluconazole's superior toxicity profile, its availability in both intravenously administered and highly bioavailable oral formulations, and the fact that its patent has recently expired, making the drug significantly less expensive than other agents, make fluconazole the preferred antifungal agent for the treatment of disseminated candidiasis in hemodynamically stable patients with susceptible isolates.
Itraconazole has similar activity against C. albicans isolates in vitro, compared with fluconazole [19] . A recent, small randomized study demonstrated that itraconazole and fluconazole had similar efficacies against candidemia in patients in a pediatric intensive care unit [20] . Nevertheless, because of both the paucity of available data on the use of itraconazole in patients with candidemia and the plethora of alternative agents for which more data are available, itraconazole cannot be considered to be a first-line agent for the treatment of candidemia at this time.
The activity of voriconazole against Candida species is superior to that of fluconazole, with MICs that are, on average, у8-fold lower than fluconazole MICs [21, 22] . A recent multicenter, international study has demonstrated that the efficacy of voriconazole is equivalent to that of standard antifungal therapy for disseminated candidiasis [9] . Kullberg et al. [9] randomized nonneutropenic patients with culture-proven candidemia to receive open-label voriconazole versus standard antifungal therapy. Standard antifungal therapy consisted of amphotericin B deoxycholate administered for у3 days, at which time the patient's therapy could be switched to fluconazole or amphotericin B deoxycholate could be continued at the investigator's discretion. Rates of cure in the modified intention-totreat populations were equivalent in both arms. In secondary analyses, the times to sterilization of blood cultures were equivalent, as were the overall and Kaplan-Meier survival rates. Finally, voriconazole demonstrated a cure rate equivalent to that associated with standard antifungal therapy for patients infected with Candida glabrata. However, because of the use of fluconazole in the standard treatment arm, it cannot be stated with certainty that the efficacy of voriconazole was equivalent to that of polyene therapy for patients infected with C. glabrata. Echinocandins. Caspofungin is a newly approved antifungal agent of a novel class of drugs called "echinocandins," the mechanism of action of which is inhibition of b 1,3 -glucan synthase, a key enzyme in fungal cell-wall synthesis. In a randomized, double-blind, multicenter study, caspofungin was as effective as amphotericin B deoxycholate for the treatment of patients with invasive Candida infections, the large majority of whom had candidemia [10] . Many of the patients in this study had proven infection of target organs. The cure rates for all patients and for patients with C. glabrata infection, as well as the overall mortality rates, were equivalent in both treatment arms. Furthermore, in multiple studies, caspofungin has been shown to be extremely safe, with very low rates of associated adverse events. Hence, caspofungin is an acceptable first-line treatment option for disseminated candidiasis.
Micafungin is the second echinocandin to receive US Food and Drug Administration approval, and it was approved for the treatment of esophageal candidiasis. The in vitro activity of micafungin against Candida species is similar to that of caspofungin, including the higher MICs noted for some strains of Candida parapsilosis. In a nonrandomized trial of salvage therapy with micafungin involving 119 patients with candidemia [23] , micafungin demonstrated an encouraging cure rate of 83%. Most recently, the results of a large, randomized, double-blind study that compared the use of micafungin (100 mg/ day) with liposomal amphotericin B (3 mg/kg/day) in 531 patients with invasive candidiasis (mostly candidemia) have been presented at an international meeting [11] . Micafungin was found to be noninferior to liposomal amphotericin B overall (end-of-therapy response rate, 90% for both micafungin and liposomal amphotericin B) and when used against non-albicans species of Candida, including C. glabrata (end-of-therapy response rates, 83% and 80% for micafungin and liposomal amphotericin B, respectively) and C. parapsilosis (end-of-therapy response rates, 89% and 87% for micafungin and liposomal amphotericin B, respectively). On the basis of the data presented, and given the similarity of the structure, pharmacology, and in vitro candidacidal activity of micafungin to those of caspofungin, micafungin appears to be a reasonable first-line option for the treatment of candidemia in nonneutropenic patients. However, final judgment on the precise role of micafungin in the anticandidal armamentarium may be reserved until publication of the peer-reviewed manuscript based on this trial occurs.
MICROBIOLOGICAL CONSIDERATIONS
Non-albicans species of Candida are increasingly common. Until the late 1980s, C. albicans caused the vast majority of cases of disseminated candidiasis. However, in recent series, C. albicans caused ∼50% of cases of hematogenously disseminated candidiasis, followed by C. glabrata, C. parapsilosis, and Candida tropicalis, each of which accounted for ∼10%-25% of cases. C. glabrata is typically the second most commonly recovered isolate in North America and much of Europe [24, 25] , but it is less commonly recovered in Spain and Latin America [21, 25] . C. parapsilosis is typically the second most commonly recovered isolate in Latin America and Spain [21, 25] . Other species, including Candida krusei (associated with !5% of cases of hematogenously disseminated candidiasis), are more rare, except in clinical settings where fluconazole prophylaxis is widely used (e.g., at cancer treatment centers), where C. krusei may cause up to 10%-15% of cases of candidemia [26] [27] [28] .
Association between species and azole susceptibility. The significance of species identification relates largely to the susceptibility of different Candida species to antifungal therapies and to azole antifungals in particular. In general, the incidence of resistance to fluconazole among C. albicans strains is extremely low, but azole resistance has been reported to develop in patients after receipt of multiple and/or prolonged courses of fluconazole therapy, including patients with advanced HIV infection and esophageal candidiasis and patients receiving prophylactic fluconazole in association with hematopoietic stem cell transplantation [29, 30] .
Most non-albicans species of Candida are susceptible to fluconazole. In contrast, C. krusei is intrinsically resistant to fluconazole because of an altered cytochrome P-450 isoenzyme [31] . Almost all C. krusei isolates demonstrate in vitro resistance to fluconazole (MIC, у16 mg/mL) [32, 33] . This resistance cannot be overcome with the use of higher drug doses. Many C. glabrata isolates are also resistant to triazoles; however, the mechanism of resistance for this species is often drug efflux, and supranormal doses may overcome resistance in certain C. glabrata isolates [34] . Overall, the frequency of fluconazole resistance (MIC, у16 mg/mL) among C. glabrata strains is ∼20%-75% [32, 33, 35, 36] . However, the majority of these strains demonstrate "susceptibility-dose-/delivery-dependent" resistance (MIC, 16-32 mg/mL) [19] , rather than high-level resistance (MIC, у64 mg/mL), and these isolates may still respond to high doses of fluconazole in vivo [19] .
Voriconazole has significantly greater in vitro activity against C. glabrata isolates and C. krusei isolates, compared with fluconazole, with у90% of C. glabrata and у98% of C. krusei isolates having voriconazole MICs of !2 mg/mL [24, 32, 33, 37] . In contrast to resistance to fluconazole, resistance to voriconazole is more frequent among C. glabrata isolates than it is among C. krusei isolates, because voriconazole binds much more effectively to the cytochrome P-450 isoenzyme in C. krusei than does fluconazole [38] .
A recent case series has suggested that the in vitro activity of voriconazole translates into clinical success in patients infected with C. krusei [39] . When salvage therapy was used, 7 (70%) of 10 patients who had invasive C. krusei infections and who had experienced failure of previous antifungal therapy responded to voriconazole therapy. In contrast, the response rate for patients infected with C. glabrata was only 38%. Although the results of the head-to-head trial conducted by Kullberg et al. [9] were somewhat reassuring, demonstrating that voriconazole and standard antifungal therapy had equivalent efficacies against candidemia due to C. glabrata, it must be emphasized that patients in the study arm receiving standard antifungal therapy had therapy switched from amphotericin B deoxycholate to fluconazole after a mean of only 4 days. Hence, a significant component of standard antifungal therapy was fluconazole, and, in this context, it is impossible to determine whether voriconazole was as effective as amphotericin or whether it was merely as effective as fluconazole against C. glabrata isolates. Finally, it is of concern that C. glabrata breakthrough infections have been seen in high-risk stem cell transplant recipients receiving voriconazole prophylaxis [40] . The weight of evidence suggests that voriconazole is a reasonable choice as an alternative agent for the treatment of C. krusei infections; its usefulness in patients infected with C. glabrata Table 3 . Doses of first-line agents for the treatment of hematogenously disseminated candidiasis.
Drug, dose
Amphotericin B deoxycholate 0.7 mg/kg/day iv for all species except Candida glabrata and Candida krusei у0.7 mg/kg/day iv for C. glabrata 1 mg/kg/day iv for C. krusei Amphotericin B lipid complex and liposomal amphotericin B 3-5 mg/kg/day iv Consider higher doses (5-10 mg/kg/day) for C. glabrata or C. krusei Fluconazole, 400-800 mg/day (6-12 mg/kg/day) iv or po Voriconazole, 300 mg (4 mg/kg) twice per day for 2 doses, then 200 mg (3 mg/kg) twice per day iv or po Caspofungin, 70-mg load, then 50 mg every day iv Micafungin, 100 mg every day iv NOTE. iv, intravenously; po, by mouth.
remains unclear. In particular, until more data are available, voriconazole is probably best avoided for C. glabrata isolates with high-level resistance to fluconazole (MIC, у64 mg/mL).
Association between species and susceptibility to polyenes and caspofungin. The treatment guidelines for Candida infections emphasize that there has been an alarming amphotericin "MIC creep" among C. glabrata isolates [19] . Furthermore, amphotericin has markedly delayed killing kinetics against C. glabrata and C. krusei in vitro, compared with its killing kinetics against C. albicans [41] . Therefore, the guidelines recommend use of amphotericin at у0.7 mg/kg/day or 1 mg/kg/day for the treatment of infections caused by C. glabrata or C. krusei, respectively, despite the increased toxicity associated with this regimen. Although rarely encountered clinically, Candida lusitaniae strains may be resistant to amphotericin [42] , and clinical failures have been noted in association with amphotericin therapy [19] . Fortunately, C. lusitaniae isolates remain susceptible to the azoles.
In contrast to polyenes and azoles, caspofungin has excellent in vitro activity against C. albicans, C. glabrata, C. krusei, and C. lusitaniae, and, in fact, against most Candida species [21, 43, 44] . However, caspofungin MICs are higher for C. parapsilosis than for other species, and, in the pivotal trial leading to the approval of caspofungin for the treatment of invasive Candida infections, 5 of 9 patients who had persistent fungemia despite receiving caspofungin therapy were infected with C. parapsilosis [10] . These data raise some concerns about the efficacy of caspofungin for the treatment of C. parapsilosis infections. Nevertheless, the overall response rates of patients infected with C. parapsilosis were the same for patients treated with caspofungin or amphotericin in the pivotal trial, thereby supporting the use of caspofungin for patients infected with C. parapsilosis. More data are needed to clarify this issue.
TREATMENT STRATEGIES
Overview of treatment. Consensus guidelines on the treatment of invasive candidiasis are available [19, 45] , and they emphasize that all patients with candidemia and disseminated candidiasis should receive antifungal therapy and that percutaneous catheters should be withdrawn if possible. The exact duration of treatment of candidemia is not well established; however, it is recommended that treatment be continued for 14 days after the last positive blood culture result is obtained and the signs and symptoms of infection have resolved [19, 45] . Doses for first-line therapies are shown in table 3.
Rational algorithm for the selection of empirical antifungal therapy for disseminated candidiasis. The following factors should be considered in the selection of empirical antifungal therapy for patients with hematogenously disseminated candidiasis ( figure 1): (1) the preference to use fluconazole for hemodynamically stable patients, because of the combination of impressive data on its efficacy in randomized studies, its highly favorable safety profile, and its very low cost; (2) the preference to avoid the use of fluconazole when there is an urgency to treat a broad range of species (e.g., for the treatment of hemodynamically unstable patients); and (3) the preference to avoid the use of fluconazole when an azole-resistant strain is likely to be the cause of the infection.
Patients who are hemodynamically unstable and/or otherwise demonstrate signs of severe sepsis require maximal therapy against the offending pathogen in the shortest possible time, because there is a high risk of a bad outcome occurring if empirical therapy that is inactive against the offending pathogen is initiated. Therefore, in a hemodynamically unstable patient, unless it is believed that the offending pathogen is very likely to be an azole-susceptible species, it is advisable to avoid the use of fluconazole. Furthermore, some clinicians may prefer to use a cidal agent (e.g., a polyene or echinocandin) for hemodynamically unstable patients, even if the offending pathogen is fluconazole susceptible, although there are no data to confirm that cidal agents are more effective than fluconazole for such patients.
Neutropenic patients are a second subset of patients for whom it may be advisable to avoid the use of static azole therapy. The use of a static agent, such as fluconazole, for neutropenic patients with candidemia should be considered carefully, especially for neutropenic patients with sepsis. However, the practice of using fluconazole for hemodynamically stable neutropenic patients is becoming more popular, in general [19] .
If a patient is neither hemodynamically unstable nor neutropenic, the next consideration in selecting antifungal therapy is the likelihood that an azole-resistant species is causing the patient's infection. Patients who, on the basis of previous culture results, are known to be colonized with C. albicans or other non-glabrata or non-krusei species of Candida are very likely to be infected with the colonizing species; fluconazole may be a reasonable choice for empirical antifungal therapy for such patients. In contrast, patients who are known to be colonized with C. glabrata or C. krusei, or patients who develop disseminated candidiasis in the face of fluconazole therapy that is ongoing or recent (within 30 days prior to the development of disseminated candidiasis), are highly likely to be infected with an azole-resistant C. glabrata or C. krusei strain. Fluconazole should be avoided as empirical therapy for such patients.
Once empirical therapy is chosen, modification of the regimen depends on the clinical course and on additional microbiological information (figure 2). For example, if nonazole therapy is initiated because of concern about an azole-resistant species, but the germ tube test result is positive for C. albicans, the patient's treatment may immediately be switched to fluconazole. If the germ tube test result is negative, but the organism is later determined to be a species other than C. glabrata or C. krusei, then therapy may reasonably be switched to fluconazole at that time.
More controversial is what to do if the patient starts receiving empirical fluconazole therapy but the offending pathogen is identified as C. glabrata several days later. The most important factor in making this decision is what has happened to the patient's condition in the intervening days. If the patient is responding to therapy with an improved temperature curve, a diminished WBC count, and/or an improved hemodynamic status, it is reasonable to continue fluconazole therapy despite the presence of C. glabrata [45] , because it is known that a significant fraction of these strains are susceptible to fluconazole. It may be advisable to use a fluconazole dose of 800 mg/ day for patients who are responding to therapy. In contrast, if the patient has not had an adequate response to therapy, switching therapy at this time is appropriate. Similarly, if the species
is not yet known but the patient's condition is not improving during the first several days while the patient is receiving fluconazole therapy, it is reasonable to broaden coverage by switching to treatment with a polyene, an echinocandin, or, possibly, voriconazole until species identification is completed.
Regardless of the clinical course, it is not advisable to use fluconazole for the treatment of patients infected with C. krusei [45] . As previously discussed in this article, an echinocandin or high-dose polyene therapy is preferred for such patients, with voriconazole serving as an alternative agent.
Patients demonstrating suboptimal responses to what should be adequate antifungal therapy should be evaluated for several common causes of therapeutic failure. These causes include lack of removal of an intravenous catheter, presence of other endovascular niduses (e.g., an infected heart valve or infected endovascular grafts or dialysis shunts), seeding of a protected site (e.g., endophthalmitis, osteomyelitis, and hepatosplenic disease), or seeding of other prosthetic devices (e.g., artificial joints and peritoneal dialysis catheters). Patients with candidemia should undergo examination of dilated retinas to rule out endophthalmitis. As for central venous catheters, infected prosthetic materials should be removed, if feasible.
Susceptibility testing should be considered in certain circumstances. Fluconazole is the only first-line agent for the treatment of disseminated candidiasis for which standardized MIC breakpoints for susceptibility have been validated by clinical data [19] . MIC breakpoints for polyenes and for voriconazole have been proposed but have not yet been well validated clinically. Nevertheless, in certain clinical circumstances, susceptibility testing is advisable. For example, knowledge of the MIC for an isolate recovered from a patient with a marginal response to fluconazole or from a patient who has experienced relapse, reinfection, or breakthrough infection during or after recent fluconazole therapy can be useful to guide the selection of appropriate therapy. In addition, voriconazole susceptibility testing of C. krusei isolates may be useful in reassuring the clinician about the use of voriconazole for such patients. Although broad recommendations regarding the clinical usefulness of susceptibility testing are difficult to make, in general, if the results of the susceptibility test would result in a change in treatment that would avoid the use of azoles or that would provide reassurance regarding the usefulness of azoles against a given isolate, then testing is reasonable.
SUMMARY
On the basis of efficacy, safety, and cost considerations, fluconazole therapy is considered to be the preferred empirical therapy for disseminated candidiasis in nonneutropenic, hemodynamically stable patients. For hemodynamically unstable patients or patients who are suspected to be infected with C. glabrata or C. krusei, a broader-spectrum agent is preferred, including amphotericin in nonlipid or lipid formulations or an echinocandin. Voriconazole may also be used in these highrisk settings, although it should be used cautiously if C. glabrata is the likely pathogen, until further data are available. Modification of empirical therapy depends largely on response to therapy, as well as the subsequent microbiological identification of the offending pathogen. Central venous catheters should be removed from all patients, if feasible, and antifungal therapy should be administered to all patients. Treatment should be continued for 14 days beyond the resolution of signs and symptoms of infection.
